Table 2. Correlation of immune cell infiltrate and clinical outcome.

Tumour Type	Immune Cell Infiltrate	Clinical Outcome
Associated with improved prognosis
Melanoma	CD4 T cell infiltrate	Better survival and higher association with spontaneous tumour regression [6–8].
Breast cancer	Intra-tumoural T cell infiltrate, including CD8 T cells and Th1 CD4 T cells.	Improved survival and earlier stage disease [9–12].
Ovarian cancer	T cell infiltrate, including CD8 T cells.	Improved survival and reduction in VEGF [13–15].
Non-small cell lung cancer	CD4 and CD8 T cell infiltrate	Improved prognosis in early stage- and advanced stage disease [16, 17].
Associated with poor prognosis
Breast cancer	High Treg	Associated with poor prognosis disease (high-tumour grade, oestrogen receptor negative, lymph node positive) and reduced disease-free and overall survival [18, 19].
Melanoma	High Treg	Increased recurrence rate [20].
Ovarian cancer	High Treg	Associated with poor prognosis [14, 21].
Non-small cell lung cancer	High Treg	Associated with increased risk of recurrence in resected early stage disease [22, 23].